This review explores the potential role of proliferative markers, including Ki‐67, PCNA, Cyclin D1, and PHH3, as predictive and prognostic indicators in pancreatic cancer management, aiming to enhance personalized treatment strategies. The gene discussed is MKI67; the disease is familial pancreatic carcinoma.